Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld
Director, Market Access & Capacity Building
Novartis Malaria Initiative
Social Forum - Geneva
February 20, 2015
Efforts by Global Health Community to control and eliminate malaria continue to yield positive results
BUT…
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
60 seconds
ONE child in Africa
dies of malaria
60s Every
Progress made 2000–2013
*Source: WHO, World Malaria Report 2014
54% decrease in mortality
rate in Africa
26% decline in
incidence globally
4.3 million
malaria deaths averted
globally
Malaria Initiative Mission and Strategy
Remain the Pharmaceutical leader in efforts contributing to Malaria Elimination
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Provide Treatment R&D for novel antimalarials
Ensure Access Build Capacity
INNOVATION & PARTNERSHIP
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
>700 Million treatments delivered without profit since 2001
72 Million treatments delivered in 2014
.. to 65 malaria
endemic countries
Responding to the unmet medical needs of infants & children
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
First child-friendly ACT introduced in 2009
– Public-private partnership with Medicines
for Malaria Venture (MMV)
– Meeting the calls from UNICEF and WHO
“to make medicines child-sized”
Helping to reduce child mortality
NIGERIA
> 250 Million pediatric formulations delivered!
Improving patient compliance with Coartem® 80/480, a new treatment with lower pill burden for adult patients
Full adult treatment course
reduced from 24 tablets to 6
tablets
Launch ongoing in malaria
endemic countries in Sub-
Saharan African
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine 6
Power of One One dollar donated. One child treated
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Public fundraising campaign to fund malaria tests and treatments
through online and mobile technology
One dollar donated. One child treated
Novartis matches up to 1 million treatments every year for 3 years
Achieved 3 million treatments for Zambia and closed the malaria
treatment gap
Campaign on-going: www.Po1.org
*US-based charity
Ground-breaking collaboration between Novartis and Malaria No More*
From ‘SMS for Life 1.0’ to ‘SMS for Life 2.0’
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
From mobile phone to TABLET
Partnering with Lagos State Ministry of Health, Nigeria
A new tablet computer-based ‘SMS for Life’ solution to support:
– Medical stock visibility and reporting
– Disease surveillance
– Health worker training
Capacity building Training, education, and awareness
Provide forum for best practice sharing among National
Malaria Control Program managers and key partners
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Best Practice Sharing Workshops
Health Systems Strengthening
Develop innovative tools to improve health workers’
knowledge of malaria case management
Pharmacist Academy to train pharmacists on malaria case
management piloted in Kenya and Nigeria
Public Awareness
Provide educational materials for school children
Accelerating malaria elimination
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
New drugs with following key properties are needed:
1. Novel mechanisms of action to anticipate emergence of
artemisinin resistance
2. Single dose treatment to improve patient compliance and target
asymptomatic patients
3. Drug that kill gametocytes and prevent parasite transmission
4. Drugs with prophylactic activity
5. P. vivax radical cure to prevent disease relapse
6. Drugs for special populations (pregnant women; G6PD deficiency)
Novartis has a strong pipeline of next generation antimalarial drugs
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Transmission Blocking
Potential KAE609
KAF156
Radical Cure PI4K (Imidazopyrazines, Pre-clin)
Prophylaxis KAF156
Single Exposure KAE609
KAF156
Artemisinin Resistance KAE609 (spiroindolone, Ph II)
KAF156 (Imidazolopiperazine, Ph II)
11
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Extensive partnership and collaboration driving industry-leading progress in drug discovery for malaria treatment
NITD in partnership with
academic centers, MMV,
BPRC, WT, and others
Accelerated drug discovery:
High throughput screening to
clinical Proof-of-Concept in
less than 6 years for both
KAE609 and KAF156
Novartis Institute for Tropical Diseases (NITD); Medicines for Malaria Venture (MMV); Biomedical Primate Research Centre (BPRC);
Wellcome Trust (WT); Kenyan Medical Research Institute (KEMRI)
12
Adequate funding
Potential spread of artemisinin resistance
Accelerating development of new drugs
Malaria diagnostics – access for all patients
Counterfeits & sub-standard antimalarials
Making access more sustainable
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
......Key Challenges
13
Increasing access
to products
Broad portfolio:
Ca. 100 drugs included
Selected based on local
disease burden (incl. EMLs)
Ensuring affordability:
Low-cost generics, vaccines,
OTC and Pharma products
Customized packs
for local needs and labeling in
local dialect
Providing education
and services
Health education:
Local health educators present on
prevention, child and maternal
health and symptom awareness
Healthcare Professional
education:
Address limited training
Supply management:
Ensure continuity of supply in
village pharmacies
Provided directly in villages via
health camps
Making an
impact
Improved access to
healthcare across 10 states,
in ca. 30,000 villages, home
to 50 million people
Partnering with thousands of
clinics and pharmacies
More than 300,000 village
health meetings and health
camps conducted, attended
by almost 11 million people
(2010-2014)
Conversion rate 12% (vs 2%
at the outset of the program)
Break-even after 30 months
Pioneering new approaches Arogya Parivar (Healthy Family) in India, started in 2007, break-even after 30 months
14 | Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
Group Social Business is now operating in new countries
India Since 2007
Vietnam Since Nov 2012
Kenya Since Mar 2012
Indonesia In rollout stage
FTEs 529
People reached 6.6 million
Patients reached 788,000
KPIs
2014
15 | Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
....NO ONE should die of malaria today
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine 16
| Social Forum | Hans Rietveld | February 20, 2015 | Driving access to medicine
This presentation was part of the Roundtable on Good practices in promoting access
to medicines during the Social Forum on 20th February, 2015 in Geneva.
Please note that the views and opinions of the speakers do not necessarily reflect
those of Novartis. Novartis only recommends the use of its products in accordance with
the locally approved package insert.
GLEM/COARTEM/0003